$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000144702823000018 Filed on March 02, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$6.687M	$6.245M	$39.02M
YoY Change	-46.85%	94.79%	255.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.552M	$4.249M	$17.83M
YoY Change	13.49%	-9.56%	4.07%
% of Gross Profit
Research & Development	$18.28M	$22.95M	$84.41M
YoY Change	-1.01%	12.29%	28.86%
% of Gross Profit
Depreciation & Amortization	$334.0K	$307.0K	$1.400M
YoY Change	-15.23%	-28.1%	-22.22%
% of Gross Profit
Operating Expenses	$24.10M	$28.81M	$104.5M
YoY Change	2.31%	20.02%	23.62%
Operating Profit	-$17.41M		-$65.46M
YoY Change	58.68%		-10.97%
Interest Expense	$198.0K	$630.0K	$1.726M
YoY Change	-60.87%	-220.0%	-39.59%
% of Operating Profit
Other Income/Expense, Net	$1.074M		$444.0K
YoY Change	-409.51%		-116.29%
Pretax Income	-$16.34M	-$21.93M	-$28.70M
YoY Change	44.32%	2.87%	272.73%
Income Tax	$0.00	$0.00	$4.444M
% Of Pretax Income
Net Earnings	-$16.34M	-$21.93M	-$69.46M
YoY Change	3.64%	2.87%	-8.91%
Net Earnings / Revenue	-244.34%	-351.19%	-178.01%
Basic Earnings Per Share	-$0.10		-$0.46
Diluted Earnings Per Share	-$0.10	-$0.14	-$0.46
COMMON SHARES
Basic Shares Outstanding	162.6M shares	156.5M shares	150.9M shares
Diluted Shares Outstanding	161.6M shares		150.9M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$146.7M	$146.9M	$146.9M
YoY Change	-11.33%	-5.41%	-5.41%
Cash & Equivalents	$40.57M	$30.78M	$30.78M
Short-Term Investments	$106.2M	$116.1M	$116.1M
Other Short-Term Assets	$3.462M	$2.874M	$2.874M
YoY Change	-41.4%	-35.34%	-35.34%
Inventory
Prepaid Expenses
Receivables	$2.664M	$1.352M	$1.352M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$152.9M	$151.1M	$151.1M
YoY Change	-11.49%	-5.93%	-5.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.853M	$5.070M	$6.814M
YoY Change	-14.32%	-15.26%	-15.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$37.36M
YoY Change			4.69%
Other Assets	$62.00K	$103.0K	$103.0K
YoY Change	-67.37%	68.85%	68.85%
Total Long-Term Assets	$38.37M	$44.28M	$44.28M
YoY Change	-40.21%	1.04%	1.04%
TOTAL ASSETS
Total Short-Term Assets	$152.9M	$151.1M	$151.1M
Total Long-Term Assets	$38.37M	$44.28M	$44.28M
Total Assets	$191.2M	$195.4M	$195.4M
YoY Change	-19.27%	-4.43%	-4.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.455M	$3.520M	$3.520M
YoY Change	105.61%	10.9%	10.9%
Accrued Expenses	$7.644M	$12.88M	$12.88M
YoY Change	-3.97%	60.59%	60.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.15M	$32.86M	$32.86M
YoY Change	-22.39%	192.82%	192.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$22.16M	$25.71M	$25.71M
YoY Change	-42.64%	7.91%	7.91%
Total Long-Term Liabilities	$22.16M	$25.71M	$25.71M
YoY Change	-42.64%	7.91%	7.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.15M	$32.86M	$32.86M
Total Long-Term Liabilities	$22.16M	$25.71M	$25.71M
Total Liabilities	$47.31M	$58.57M	$58.57M
YoY Change	-33.4%	67.11%	67.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.220B	-$1.204B
YoY Change	6.09%	6.12%
Common Stock	$1.339B	$1.319B
YoY Change	3.18%	2.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$143.9M	$136.9M	$136.9M
YoY Change
Total Liabilities & Shareholders Equity	$191.2M	$195.4M	$195.4M
YoY Change	-19.27%	-4.43%	-4.43%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$16.34M	-$21.93M	-$69.46M
YoY Change	3.64%	2.87%	-8.91%
Depreciation, Depletion And Amortization	$334.0K	$307.0K	$1.400M
YoY Change	-15.23%	-28.1%	-22.22%
Cash From Operating Activities	-$27.30M	-$16.99M	-$35.36M
YoY Change	-232.41%	-13.34%	-47.65%
INVESTING ACTIVITIES
Capital Expenditures	$117.0K	$134.0K	$512.0K
YoY Change	56.0%	-331.03%	-36.71%
Acquisitions
YoY Change
Other Investing Activities	$16.80M	$12.82M	-$74.43M
YoY Change	-128.0%	-258.95%	527.1%
Cash From Investing Activities	$16.68M	$12.68M	-$74.94M
YoY Change	-127.77%	-256.16%	491.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$20.42M	11.08M	$31.81M
YoY Change	77.77%	-81.25%	-76.82%
NET CHANGE
Cash From Operating Activities	-$27.30M	-16.99M	-$35.36M
Cash From Investing Activities	$16.68M	12.68M	-$74.94M
Cash From Financing Activities	$20.42M	11.08M	$31.81M
Net Change In Cash	$9.798M	6.776M	-$78.51M
YoY Change	-135.05%	-78.42%	-237.65%
FREE CASH FLOW
Cash From Operating Activities	-$27.30M	-$16.99M	-$35.36M
Capital Expenditures	$117.0K	$134.0K	$512.0K
Free Cash Flow	-$27.42M	-$17.12M	-$35.87M
YoY Change	-233.46%	-12.4%	-47.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-34949
CY2022	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0597776
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Veterans Circle
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Warminster
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	18974
CY2022	dei	City Area Code CityAreaCode	267
CY2022	dei	Local Phone Number LocalPhoneNumber	469-0914
CY2022	dei	Security12b Title Security12bTitle	Common shares, without par value
CY2022	dei	Trading Symbol TradingSymbol	ABUS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	290424678	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	162570989	shares
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	184300000	usd
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30776000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109282000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	116137000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	46035000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1352000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	899000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2874000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4445000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	151139000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	160661000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5070000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5983000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	37363000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	35688000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1744000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2092000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	61000	usd
CY2022Q4	us-gaap	Assets Assets	195419000	usd
CY2021Q4	us-gaap	Assets Assets	204485000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16029000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10838000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16456000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	372000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	383000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32857000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11221000	usd
CY2022Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	10365000	usd
CY2021Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	16296000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5999000	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7531000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5298000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1815000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2231000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	58567000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	35046000	usd
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	157455363	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	157455363	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144987736	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	144987736	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1318737000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1286636000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72406000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	65485000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1203803000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1134347000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50488000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48335000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	136852000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	169439000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	195419000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	204485000	usd
CY2022	us-gaap	Revenues Revenues	39019000	usd
CY2021	us-gaap	Revenues Revenues	10988000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	84408000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65502000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17834000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17136000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2233000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1872000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	104475000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	84510000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-65456000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-73522000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2192000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	127000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1726000	usd
CY2021	us-gaap	Interest Expense InterestExpense	2857000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-22000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	5000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	444000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2725000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-65012000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-76247000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4444000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-69456000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-76247000	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	usd
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	12139000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-69456000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-88386000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150939337	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150939337	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106242452	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106242452	shares
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-2153000	usd
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-164000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71609000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76411000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	101966000	usd
CY2021	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6385000	usd
CY2021	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	263000	usd
CY2021	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	134665000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	461000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2110000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-164000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-76247000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	169439000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7182000	usd
CY2022	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	26000	usd
CY2022	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	20324000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	395000	usd
CY2022	abus	Stock Issued During Period Value New Issues Share Purchase Agreement StockIssuedDuringPeriodValueNewIssuesSharePurchaseAgreement	10973000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	122000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2153000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-69456000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	136852000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-69456000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-76247000	usd
CY2022	us-gaap	Depreciation Depreciation	1427000	usd
CY2021	us-gaap	Depreciation Depreciation	1753000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7182000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	6424000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2233000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1872000	usd
CY2022	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	7653000	usd
CY2021	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	6108000	usd
CY2022	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	1722000	usd
CY2021	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	2850000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	54000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-999000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	453000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-413000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2430000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1025000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5216000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1911000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	22455000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-405000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-374000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35356000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67532000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	130430000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	82219000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	56000000	usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	70350000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	512000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	809000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74942000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12678000	usd
CY2022	abus	Proceeds From Issuance Of Common Stock Share Purchase Agreement ProceedsFromIssuanceOfCommonStockSharePurchaseAgreement	10973000	usd
CY2021	abus	Proceeds From Issuance Of Common Stock Share Purchase Agreement ProceedsFromIssuanceOfCommonStockSharePurchaseAgreement	0	usd
CY2022	abus	Proceeds From Issuance Of Common Stock Open Market Sale Agreement ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement	20324000	usd
CY2021	abus	Proceeds From Issuance Of Common Stock Open Market Sale Agreement ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement	134665000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	122000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2110000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	395000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	461000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31814000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	137236000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-22000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-78506000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	57031000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109282000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52251000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30776000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109282000	usd
CY2022	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0	usd
CY2021	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	12139000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Organization<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arbutus Biopharma Corporation (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company’s current focus areas include Hepatitis B virus (“HBV”), SARS-CoV-2 and other coronaviruses. To address HBV, the Company is developing an RNA interference (“RNAi”) therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV infection (“cHBV”) by suppressing viral replication, reducing surface antigen and reawakening the immune system. The Company believes its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. AB-729 is currently being evaluated in multiple phase 2 clinical trials. The Company also has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, including SARS-CoV-2, where the Company has nominated a compound and has begun IND-enabling pre-clinical studies. In addition, the Company is also exploring oncology applications for its internal PD-L1 portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the Company had an aggregate of $184.3 million in cash, cash equivalents and investments in marketable securities. The Company had no outstanding debt as of December 31, 2022. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19 Impact </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the effects of COVID-19, which has caused significant disruptions around the world. Measures implemented around the world in attempts to slow the spread of COVID-19 have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, including shortages and delays in the supply chain, and prohibitions in certain countries on enrolling patients in new clinical trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span>While the Company has been able to progress with its clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will materially impact the Company’s plans and timelines in the future.
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	184300000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2022Q4	abus	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses and contingent liabilities as of the end or during the reporting period. Actual results could significantly differ from those estimates. Significant estimates in the accompanying consolidated financial statements impact contingent consideration, income tax recoveries, stock-based compensation, clinical trial accruals and the sale of future royalties liability.</span></div>
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11400000	shares
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22833922	shares
CY2022	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.0875
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22833922	shares
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></div>
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7500000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2200000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5298000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2233000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7531000	usd
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3426000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1872000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5298000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	38129000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	35775000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	116100000	usd
CY2022Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	37400000	usd
CY2021Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	35700000	usd
CY2022	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
CY2021	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
CY2022Q4	abus	Lessee Operating Lease Numberof Leases LesseeOperatingLeaseNumberofLeases	1	lease
CY2022Q4	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P5Y
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	usd
CY2022	abus	Fixed Lease Cost FixedLeaseCost	600000	usd
CY2021	abus	Fixed Lease Cost FixedLeaseCost	600000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	100000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	100000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	641000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	650000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	598000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	616000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	635000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	654000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	134000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2637000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	450000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2187000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15871000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10801000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5070000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15357000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9374000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5983000	usd
CY2022	us-gaap	Depreciation Depreciation	1400000	usd
CY2021	us-gaap	Depreciation Depreciation	1800000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16029000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3520000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3174000	usd
CY2022Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	3730000	usd
CY2021Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	4279000	usd
CY2022Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	8261000	usd
CY2021Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	2371000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	512000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	983000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	31000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10838000	usd
CY2021Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	16296000	usd
CY2020Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19554000	usd
CY2022	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	7653000	usd
CY2021	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	6108000	usd
CY2022	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	1722000	usd
CY2021	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	2850000	usd
CY2022Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	10365000	usd
CY2021Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	16296000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	22455000	usd
CY2022Q4	abus	Alnylam Entitlements AlnylamEntitlements	2	product
CY2022	us-gaap	Revenues Revenues	39019000	usd
CY2021	us-gaap	Revenues Revenues	10988000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22833922	shares
CY2022Q4	us-gaap	Employee Stock Ownership Plan Esop Shares In Esop EmployeeStockOwnershipPlanESOPSharesInESOP	1500000	shares
CY2022Q4	abus	Common Stock Discount On Shares Percentage CommonStockDiscountOnSharesPercentage	0.15
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	171224	shares
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	196335	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1132441	shares
CY2022	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	200000	usd
CY2021	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	300000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7182000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6424000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	13200000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17554000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-23864000	usd
CY2022	abus	Effective Income Tax Rate Reconciliation Tax Withholding EffectiveIncomeTaxRateReconciliationTaxWithholding	4444000	usd
CY2021	abus	Effective Income Tax Rate Reconciliation Tax Withholding EffectiveIncomeTaxRateReconciliationTaxWithholding	0	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	761000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-1041000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	869000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	4292000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	4444000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	0	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	324000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	611000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14563000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15928000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	5625000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4840000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	504000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	456000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4444000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3700000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3800000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11700000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-28700000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-93700000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-7700000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-80700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	16500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	83564000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	90255000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16791000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16968000	usd
CY2022Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	461000	usd
CY2021Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	634000	usd
CY2022Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	2799000	usd
CY2021Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	4400000	usd
CY2022Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	93000	usd
CY2021Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	549000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3375000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3375000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3633000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3741000	usd
CY2022Q4	abus	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Stock Options DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions	3681000	usd
CY2021Q4	abus	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Stock Options DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions	3309000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	16471000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	0	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	1507000	usd
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	387000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	153000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1341000	usd
CY2022Q4	abus	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	145287000	usd
CY2021Q4	abus	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	130724000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	145287000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	130724000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22833922	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
abus-20221231_pre.xml	Edgar Link	unprocessable
0001447028-23-000018-index-headers.html	Edgar Link	pending
0001447028-23-000018-index.html	Edgar Link	pending
0001447028-23-000018.txt	Edgar Link	pending
0001447028-23-000018-xbrl.zip	Edgar Link	pending
abus-20221231.htm	Edgar Link	pending
abus-20221231.xsd	Edgar Link	pending
abus-20221231_g1.jpg	Edgar Link	pending
abus-20221231_cal.xml	Edgar Link	unprocessable
abus-20221231_def.xml	Edgar Link	unprocessable
abus-20221231_htm.xml	Edgar Link	completed
exhibit1041formofrsuawarda.htm	Edgar Link	pending
exhibit211listingofsubsidi.htm	Edgar Link	pending
exhibit231eyconsent2022.htm	Edgar Link	pending
exhibit31110-kcertceo2022.htm	Edgar Link	pending
exhibit31210-kcertcfo2022.htm	Edgar Link	pending
exhibit321soxcertceo2022.htm	Edgar Link	pending
exhibit322soxcertcfo2022.htm	Edgar Link	pending
exhibit41descriptionofsecu.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
abus-20221231_lab.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2023 Q1 Form 10-K Financial Statement

#000144702823000018 Filed on March 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2023 Q1 Form 10-K Financial Statement

#000144702823000018 Filed on March 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus